Nina is a trusted adviser in intellectual property law, helping clients successfully navigate complex patent disputes in particular in the life sciences and tech sectors. Her multidisciplinary approach enables businesses to address complicated legal challenges while protecting and optimising the value of their intellectual property.
Nina specialises in simplifying complexity where different legal challenges collide, addressing issues at intersection of patent law, pharmaceutical law, national reimbursement rules, competition and antitrust law. With in-depth sector expertise, she offers integrated advice aligned with clients’ commercial objectives.
In addition, Nina provides comprehensive counsel on contracts dealing with IP rights, as well as on IP issues in the context of international transactions.
Nina regularly acts as lead counsel in complex patent litigation in front of German courts and the Unified Patent Court. She is particularly proud of the Freshfields team representing clients both on the offense and defense side across all sectors at the forefront of the newly established Unified Patent Court.
Nina regularly speaks and publishes on IP matters. She is a member of the editorial board of the GRUR Patent, a practitioner-focussed publication addressing the most important current issues in patent matters in Europe. She was named one of “40 under 40” by Capital, one of Germany’s leading business magazines, and one of “Europe’s Best Up-and-Coming Female Lawyers” by law.com.
Before joining Freshfields, Nina wrote a doctoral thesis on patent strategies within the pharmaceutical sector at the Max Planck Institute for Innovation and Competition as a scholarship holder, underscoring her deep understanding of IP strategy and innovation.
Fluent in German and English.
- Representation of Moderna in enforcement of COVID-19-related patents against BioNTech/Pfizer;
- Representation of various companies in offense and defense UPC proceedings, including Lenovo, Kodak, Becton Dickinson and HP;
- Representation of tech companies in disputes concerning standard-essential patents, including Lenovo in disputes against Nokia and InterDigital concerning video coding and cellular SEPs;
- Representation of Novartis in various patent disputes, e.g. concerning the blockbusters Glivec®, Afinitor®, Gilenya® and Ritalin® (including enforcement of so-called second medical use patents);
- Representation of Alexion against Amgen in the assertion of regulatory market exclusivity rights protecting orphan drugs, including proceedings at the CJEU;
- Advising various companies in M&A transactions, including Grünenthal GmbH with its acquisition of the Nebido® business;
- Representation of various companies (including Palantir and BMS) in complex entitlement proceedings.

